ClinicalTrials.gg
CompletedNCT02142127Updated May 29, 2015

Mass Balance Study of 14C-labelled GFT505 in Healthy Volunteers

A Phase 1 interventional study of 14C-labelled GFT505 120 mg in Healthy, sponsored by Genfit. Completed at 1 site in Belgium. Open to male participants aged 55 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-05-29.

Sponsored by Genfit · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
55 Years to 65 Years
Sex
Male
01

Study summary

Human mass-balance studies with radiolabelled study drug are needed to evaluate the amount of drug that is recovered over time via different elimination routes of the body, i.e., whole blood, blood cells, plasma, urine, feces, and expired air. The ideal case is to be able to demonstrate a (near) complete recovery (≥95 %) of the administered dose.

A good understanding of the metabolic pathway of the study drug is equally important. Mass-balance data, together with metabolic profiles in excreta, are used to characterize the biotransformation pathways of a drug and to help evaluate its drug-drug interaction potential.

To this purpose, in this study, blood, urine, and feces are collected to investigate the metabolic profile of GFT505, and plasma and urine are collected to investigate the non-radioactive pharmacokinetics of GFT505 and its principle metabolite GFT1007. Other metabolites will be investigated in plasma and urine according to the radioactivity results. Non-radioactive pharmacokinetics of GFT505 and metabolites in feces will be investigated according to the radioactivity results.

Read the detailed description

This is a Phase I open-label, single oral dose and single center study of 14C-labelled GFT505 and its metabolites in healthy subjects.

After an overnight fast, subjects will be administered one dose of 14C-labelled GFT505 containing an equivalent of 120 mg of the compound with 240 mL of non-carbonated water. The total amount of administered radiocarbon will be 1.63-1.81 megaBecquerel (MBq) (44.1-48.8 μCi).

Blood, urine, and feces will be collected at scheduled time intervals from before administration of the radiolabelled study drug throughout confinement at the clinical center and thereafter, if needed. Several samples of expired carbon dioxide will be obtained up to 48 h after the administration of radiolabelled study drug.

Radiocarbon will be assayed in all available samples (whole blood, plasma, urine, feces, and expired air) by liquid scintillation spectrometry. The metabolic profile of GFT505 will be assayed in plasma, urine, and feces. Non-radioactive pharmacokinetics of GFT505 and its principle metabolite GFT1007 will be assayed in plasma and urine. Other metabolites will be investigated in plasma and urine according to the radioactivity results. Non-radioactive pharmacokinetics of GFT505 and metabolites in feces will be investigated according to the radioactivity results.

02

Conditions studied

  • Healthy

Keywords

  • GFT505
  • Mass balance
  • Pharmacokinetics
  • Metabolites
  • Healthy subjects
  • Healthy male volunteers
03

In context

Lead sponsor

Genfit is the lead sponsor of 23 studies on the registry; 2 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 4 (44%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
55 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy Caucasian males aged 55 to 65 years inclusive
  • (BMI) ≥ 18 ≤ 30 kg/m²
  • Fitzpatrick skin type \< 4
  • No abnormalities in hematology and clinical chemistry parameters, blood pressure (BP) and heart rate (HR) (supine), or results

Exclusion criteria

Exclusion Criteria:

  • History or presence of any hepatic, renal, respiratory, cardiovascular, neurologic, gastrointestinal, endocrine, immunologic, musculoskeletal, or hematologic disorder capable of altering the absorption, metabolism, or elimination of drugs, or capable of constituting a risk factor when taking the study drug, as judged by the investigator;
  • as calculated by the Cockcroft-Gault formula less than 60 mL/min;
  • History of irregular bowel movements such as regular episodes of diarrhea, constipation (less than a mean of one bowel movement per day) or irritable bowel movement;
  • Planning to become a father or to donate sperm within 3 months after the administration of study drug;
  • History or presence of drug addiction (positive drug screen for amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, or opiates) or excessive use of alcohol (daily intake exceeding 2 units/day);
  • Current use of nicotine containing products, i.e., more than 5 cigarettes or equivalent/day and the inability to stop using nicotine containing products during confinement in the clinical center;
  • Large caffeine consumption (daily average of more than 6 cups of coffee or tea or more than 1L of caffeine-containing beverages) within the last year;
  • Plasma levels of , AST, or alkaline phosphatase (ALP) ≥1.5 x upper limit of laboratory normal range ();
  • Blood donation or loss of significant amount of blood within 12 weeks prior to dosing;
  • Inability to understand the constraints of full urine and stool collection or inability to collect urine;
  • Use of any drug treatment that could affect the outcome of the study from 14 days before the administration of the radiolabelled study drug (2 months for enzyme-inducing drugs) or 5 times the half-life of the medication, or anticipated use of concomitant therapy (except paracetamol) during the study;
  • Exposure to ionizing radiations (except routine or dental radiography or radiography of the extremities), including participation in studies with radiolabelled compounds, or exposure to radioisotopes within one year prior to entry into the present study;
  • Participation in another clinical study within 12 weeks prior to entry into the present study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    14C-labelled GFT505 120 mg

    Drug: 14C-labelled GFT505 120 mg

Interventions

  • Drug14C-labelled GFT505 120 mg
06

What researchers measure

Primary outcomes

  1. Excretion balance of radiocarbon in whole blood, blood cells, plasma, urine, feces, and expired air after a single oral dose of 14C-labelled GFT505.

    Blood, urine, and feces will be collected at scheduled time intervals from before administration of the radiolabelled study drug throughout confinement at the clinical center and thereafter, if needed. Several samples of expired carbon dioxide will be obtained up to 48 h after the administration of radiolabelled study drug. Radiocarbon will be assayed in all available samples (whole blood, plasma, urine, feces, and expired air) by liquid scintillation spectrometry.

    Time frame: 0-19 days

Secondary outcomes

  1. Metabolic profile of GFT505 in plasma, urine, and feces.

    The metabolic profile of GFT505 will be assayed in plasma, urine, and feces. Non-radioactive pharmacokinetics of GFT505 and its principle metabolite GFT1007 will be assayed in plasma and urine. Other metabolites will be investigated in plasma and urine according to the radioactivity results. Non-radioactive pharmacokinetics of GFT505 and metabolites in feces will be investigated according to the radioactivity results.

    Time frame: 0- 19 days

  2. Safety parameters

    Safety assessment will be based on adverse events (AEs), clinical laboratory tests, electrocardiogram (ECG), vital signs, and physical examination.

    Time frame: 0 - 19 days

07

Study locations

1 site
  • SGS Life Science Services
    Antwerp, 2060, Belgium
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2014, a primary completion of Jun 2014 and a completion of Apr 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2014
First posted
May 20, 2014
Start
Apr 2014
Primary completionActual
Jun 2014
CompletionActual
Apr 2015
Last update
May 29, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02142127
Lead sponsor
Genfit
Collaborators
SGS Life Sciences, a division of SGS Belgium NV
Responsible party
Sponsor
First posted
May 20, 2014
Start date
Apr 2014
Primary completion
Jun 2014
Completion
Apr 2015
Last update
May 29, 2015

Study contacts

Sophie Megnien, MD
study director · Chief Medical Officer, Genfit

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion